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Abstract The aging lung is increasingly susceptible to infectious disease. Changes in pulmonary physiology and function
are common in older populations, and in those older than 60 years, pneumonia is the major cause of infectious death.
Understanding age-related changes in the innate and adaptive immune systems, and how they affect both pulmonary and
systemic responses to pulmonary challenge are critical to the development of novel therapeutic strategies for the treatment
of the elderly patient. In this observational study, we examined age-associated differences in inflammatory responses to
pulmonary challenge with cell wall components from Gram-positive bacteria. Thus, male Sprague–Dawley rats, aged
6 months or greater than 18 months (approximating humans of 20 and 55–65 years), were challenged, intratracheally, with
lipoteichoic acid and peptidoglycan. Cellular and cytokine evaluations were performed on both bronchoalveolar lavage
fluid (BAL) and plasma, 24 h post-challenge. The plasma concentration of free thyroxine, a marker of severity in non-
thyroidal illness, was also evaluated. The older animals had an increased chemotactic gradient in favor of the airspaces,
which was associated with a greater accumulation of neutrophils and protein. Furthermore, macrophage migration inhi-
bitory factor (MIF), an inflammatory mediator and putative biomarker in acute lung injury, was increased in both the
plasma and BAL of the older, but not young animals. Conversely, plasma free thyroxine, a natural inhibitor of MIF, was
decreased in the older animals. These findings identify age-associated inflammatory/metabolic changes following pul-
monary challenge that it may be possible to manipulate to improve outcome in the older, critically ill patient.
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Introduction
In normal individuals, the maximum functional ability of
the lungs occurs between the ages of 20–25 years, after
which there is a progressive decline in performance [1].
The changes are mainly associated with decreases in static
elastic recoil, compliance of the chest wall, and in the
strength of respiratory muscles. In later life, the suscepti-
bility to lung infection also increases, and pneumonia
occurs in around 25–44 cases per 1000 non-institutional-
ized elderly individuals [2], and in those older than
65 years old, pneumonia is the major cause of infectious
death [3]. Studies of critically ill patients have identified
advanced age and pulmonary staphylococcal infection as
leading causes of sepsis [4]. Acute lung injury (ALI) or the
adult respiratory distress syndrome (ARDS), as it is now
more formally known in humans [5], is a major compli-
cation of nosocomial pneumonia [6] and is associated with
acute inflammation leading to disruption of the lung
epithelial and endothelial barriers. The inflammation is
associated with greatly increased accumulation of neu-
trophils and other inflammatory cells induced by increased
chemotaxins within the alveolae [7–9]. The injury is also
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associated with increased accumulation of the proinflam-
matory mediator macrophage migration inhibitory factor
(MIF) within the airspaces [10]. MIF has been shown to be
released by the lungs, into the systemic circulation, where
it induces cardiocirculatory depression [11]. Because of its
importance in acute inflammation, several groups have
developed inhibitory antibodies [12–14] and synthetic
small molecule inhibitors of MIF [15–18], and shown that
they can prevent morbidity and mortality associated with
endotoxemia and sepsis [16, 18–20]. Interestingly, MIF has
the ability to override the anti-inflammatory activity of
glucocorticoids [21], which, although their use remains
controversial, have been used as therapeutic agents in the
treatment for ARDS [22–24]. Furthermore, recent studies
have shown that the thyroid hormone thyroxine, which is
often decreased in critically ill patients, even in the absence
of thyroidal illness [25], is a natural inhibitor of the
proinflammatory active site of MIF [26].
In this observational study, components of the cell wall of
Gram-positive bacteria, such as S. aureus, were used to incite
an acute lung inflammation. We then evaluated age-depen-
dent changes in the inflammatory response, in both the blood
and alveolar compartments, at 24 h following the insult.
Methods
Animals Studies
All animal experiments received prior approval by the
Institutional Animal Care and Use Committee of The
Feinstein Institute. Male Sprague–Dawley rats (4 or
12 months of age) were purchased from Charles River
(Kingston, NY). The latter were housed under standard
conditions and provided with standard rodent chow and
water, until experimentation at 18–20 months of age.
Experimental Protocol
Three groups were investigated. Young (\6 months saline;
\6 months LTA ? PGN) and old ([18 months
LTA ? PGN). Each rat (n = 6 per group) was weighed and
then anesthetized to a surgical plane using isoflurane. The
tracheawas then surgically exposed and cell wall components
from Gram-positive bacteria lipoteichoic acid (0.15 mg) and
peptidoglycan (0.5 mg), or saline alone in 100 ml sterile
0.9 % saline, was instilled intratracheally using a 29-gauge
needle. The woundwas then closed using 5.0 silk sutures, and
the animals were allowed to recover. Once ambulant, they
were returned to normal housing and allowed food and water
ad libitum. After 24 h, the animals were re-anesthetized with
isoflurane and exsanguinated via cardiac puncture, and the
blood was collected for analysis. Postmortem, the lungs were
lavaged with two aliquots (7 ml each) of sterile saline
(0.9 %w/v). The bronchoalveolar lavage fluid (BAL) from
each lavage was collected in separate tubes. The tubes were
centrifuged, and supernatant was stored in-80 C. Only the
supernatant from the first tube was used for measuring
chemokines, cytokines, and protein content, whereas BALF
from both tubes was used for cell counting [27].
Analysis of Bronchoalveolar Lavage Fluid
BAL cells were mixed with 0.5 ml of 0.2 % saline for 10 s
to lyse any residual erythrocytes. The cells were then
resuspended in 10 ml Hank’s buffered salt solution
(HBSS). Total cell number was determined with a hemo-
cytometer. Slides were prepared using a Shandon cyto-
centrifuge (Shandon Scientific, London, UK), and cells
were stained with Wright-Giemsa stains (HEMA 3 Stain
Set, Fisher Scientific, Pittsburgh, PA) for differential cell
counting. Counts were made on at least 200 cells per slide.
Protein concentrations in BAL were assessed by BCA
method (Pierce, Rockford, IL).
Commercially available enzyme-linked immunosorbent
assay (ELISA) kits were used to assay MIF and KC
(MyBioSource, San Diego, CA) and free thyroxine (Gen-
way Biotech, Inc., San Diego, CA) following the manu-
facturers’ instructions.
Statistical Analysis
Data are presented as mean ± standard deviation. One-
way ANOVA was used to evaluate the statistical signifi-
cance of the results. Difference with p value\ 0.05 was
considered significant.
Results
Body Weight Increased with Age
Sprague–Dawley rats can live up to 3.5 years, and males
reach an adult body weight of between 450 and 520 g
around 12 weeks old. In the current study, the body
weights of the rats were 473 ± 38 g in the\6-month group
and 641 ± 45 g in the[18-month group (Fig. 1). How-
ever, in the current study, animals were challenged with the
same amount of LTA and PGN, and it was not titered with
respect to body weight.
Polymorphonuclear Leukocyte (Neutrophil) Influx
into the Airspaces
Neutrophils accumulate at a site of inflammation by
responding to a chemotactic gradient. In rats, KC (CXCL1)
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and its cellular receptor CXCR2 have been shown to be a
major chemokine for the pulmonary recruitment of neu-
trophils [28]. Therefore, we measure the concentration of
this chemokine in both plasma and the airspaces, and
assessed its association with the accumulation of neu-
trophils within the alveolae. Following pulmonary chal-
lenge, there was a significant increase (p = 0.05) in the
percentage of neutrophils in the blood of the \6-month
group (69 ± 13 %) compared to controls (39 ± 10 %).
However, in the older group [18 months, there was no
significant increase in the percentage of blood neutrophils
(42 ± 14 %). Concurrently, in the BAL, the total number
of neutrophils significantly increased from control values
in both groups of rats treated with LTA–PGN (Fig. 2a).
The neutrophilic influx was associated with a significant
accumulation of KC within the airspaces of the older ani-
mals (43.8 ± 18.5 ng/ml) compared to controls
(16.5 ± 4.0) and\6-month group (21.6 ± 6.6). However,
this was not reflected in the plasma accumulation of KC
controls (4.2 ± 5.9 ng/ml); \6 months (3.7 ± 1.4);
[18 months (2.3 ± 1.5). Since neutrophil chemotaxis
depends on the movement of cells along a chemotactic
gradient, we assessed the ratio of the concentration of KC
in the BAL and plasma (Fig. 2b). While there was no
significant difference between the younger groups, in this
respect, the[18 months was significantly greater than the
other two groups. It should be noted that BAL is approx-
imately 100-fold more dilute than the epithelial lining fluid
that it samples [7]. Thus, there is a considerable chemo-
tactic gradient between the blood and alveolar spaces in the
LTA–PGN challenged animals. The influx of neutrophils
was associated with significantly increased accumulation
of protein (p\ 0.05) in the \6-month group
(427 ± 208 lg/ml) and [18-month-old group
(584 ± 297 lg/ml) within the alveolar space of challenged
animals compared to controls (108 ± 40 lg/ml), suggest-
ing that some injury to the airspaces had occurred in each
of the challenged groups.
Macrophage Migration Inhibitory Factor
Accumulation
While MIF is found within the airspaces of normal lungs,
there is a significant increase in accumulation in the alveolar
airspaces of patients with ARDS [10]. In addition, animal
studies suggest that there is enhanced MIF expression in the
alveolar endothelium and infiltrating macrophages in ARDS
[14, 29], and that the lungsmay act as an inflammatory organ
releasingMIF into the systemic circulation [30], where it can
induce cardiocirculatory depression [11]. Therefore, we
examined the concentration of MIF in blood and BAL fol-
lowing pulmonary challenge. At 24 h post-challenge, there
was only an increase inMIF of the plasma of the[18-month-
old group (Fig. 3a). However, a significant increase in
plasma MIF was only see in two (33 %) of the animals. A
more profound increase in MIF concentration was noted
within the airspaces of the older group (Fig. 3b).
Free Thyroxine Evaluation
A characteristic finding in patients with critical illness is an
alteration in circulating thyroid hormone levels including
thyroxine (T4). The changes in thyroid hormone concen-
trations are directly correlated to the severity of the disease
and are associated with poor survival [31]. Accordingly, we
measured plasma free T4 in the rats following pulmonary
challenge (Fig. 4). The median free T4 was significantly
Fig. 1 Body weights prior to pulmonary challenge. The weights of
the older animals were significantly greater than those of the younger
group (*p\ 0.05)
Fig. 2 Neutrophil
accumulation in the airspaces of
the lungs a was significantly
greater in the rats challenged
with LTA and PGN than in
controls. b The ratio of the KC
concentration in the BAL and
Plasma KC was significantly
higher in the[18-month group
than in either of the other two
groups (*p\ 0.05)
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lower in the older age group (1.02 ng/dl) than the controls
(1.55 ng/dl). However, there was no difference between the
young group (1.20 ng/dl) and controls.
Discussion
The ability of the body to mount a concerted response is an
evolutionary advantage. In the case of bacterial challenges,
our body is tested by a diverse, complex and dynamic
challenge, and must adapt its constitutive functions to repel
the threat. In many cases, the response to the challenge is
appropriate and homeostasis maintained. However, there
are other situations in which the body’s overall inflam-
matory response is seemingly inappropriate, lacking
effectiveness, and leads to detrimental effects and even
death.
Infection by the Gram-positive bacteria Staphylococcus
aureus or Streptococcus pneumonia is a common cause of
pneumonia, especially in elderly patients [32–34]. The
elderly are at increased risk of pneumonia due to age-re-
lated deterioration of lung function [35]. Studies of criti-
cally ill patients have identified advanced age and
pulmonary S. aureus infection as leading causes of sepsis
[4]. During the progression of infection and pneumonia,
ALI can develop. ALI is a major clinical condition which
affects nearly 200,000 individuals annually in the USA
[36] and a major complication of nosocomial pneumonia
[37]. The clinical manifestations include severe hypoxemia
with acute onset and bilateral infiltrates on chest radiog-
raphy [38]. Although effective ventilator and fluid man-
agement strategies have been developed, mortality remains
high at 25–35 % [39–41]. Age is a critical determinant of
the incidence and mortality of ALI [incidence: 16 per
100,000 person-years in young (15–19 years of age) and
306 per 100,000 person-years (75–84 years of age) mor-
tality: 24 % (15–19 years) to 60 % ([85 years)] [36].
Critically ill patients with ALI or its most severe form
ARDS, have an increased capillary permeability, which
results in significant fluid imbalance, oncotic pressure
changes, pulmonary edema, and alveolar collapse [42].
While comorbidities such as chronic obstructive pul-
monary disease (COPD) and cardiovascular disease are
major risk factors for pneumonia in the elderly, it is also
clear that there are changes in the inflammatory response
even in the healthy individual [43]. While studies show that
pro-inflammatory cytokines in blood and tissues are higher
than in their young counterparts [44, 45], this may not be
the complete, or indeed the fundamental, reason for the
increased mortality. Thus, it remains unclear whether there
are alterations in magnitude of the response or whether the
normally highly orchestrated sequence of events is dys-
regulated. The sequence of events that occur in the
inflammatory response is critical to the effectiveness of that
response.
Animal studies involving older animals are expensive
and often more difficult to perform due to the ‘‘fragility’’ of
the animal with greater morbidity and mortality associated
with this group. Also, as in the current study, the variability
of the responses in the older animals is greater than their
younger counterparts. Therefore, many of the studies
involving acute lung inflammation, ALI, and sepsis are
performed in young animals, and there is much less
information about the pathophysiology of acute inflam-
mation, which is specific to older patients [46]. However,
studies have shown important age-associated increase in
mortality, hypothermia, and induction of IL-6 following
Fig. 3 MIF concentration in
both the plasma (a) and the
airspaces (b) was significantly
greater in the older animals than
in controls (*p\ 0.05) or the
younger animals following an
identical pulmonary challenge
(#p\ 0.05)
Fig. 4 Plasma free thyroxine (fT4) was significantly decreased in the
older animals 24 h post-pulmonary challenge (*p\ 0.05)
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Gram-negative or [47] Gram-positive [48] challenge.
While the current study only examines one dose of bacte-
rial toxin and one time point of sampling, it highlights
some pertinent differences between the groups and changes
that occur following pulmonary challenge in a rat model of
acute inflammation, and the differing response to an
identical challenge in the older animal group. First, the
body weights of the older age group, prior to challenge,
were significantly greater than controls. Starr et al. [49]
have shown that white adipose tissue is a major source of
interleukin-6 (IL-6), a proinflammatory cytokine mediating
the severity of sepsis [50]. Furthermore, obesity is associ-
ated with an increased number of activated circulating
neutrophils [51]. Previous studies have shown that acti-
vated neutrophils have a longer life span than their quies-
cent counterparts [52]. Interestingly, 24 h post-challenge,
there was no change in the percentage of neutrophils in the
blood of the older group, but there were more neutrophils
in the airspaces. The increased accumulation was associ-
ated with a more profound chemotactic gradient, in favor
of the airspaces, in the older animals (Fig. 2). This suggests
that in the younger animals, the neutrophil recruitment had
terminated earlier than in the older group. Perhaps more
importantly, the inflammatory effects of the chemokine
may be more profound in the older group. This is because
KC and its human counterpart Interleukin-8 not only
induce neutrophil chemotaxis, but at higher concentrations
initiate neutrophil degranulation and the generation of
hydrogen peroxide and superoxide anion [28, 53]. Of note,
elevated levels of interleukin-8 are present in the airspaces
of patients with the adult respiratory distress syndrome and
are associated with increased mortality [7].
We also found increased accumulation of MIF in both
the plasma and airspaces of the older animals 24 h post-
challenge. MIF is a relatively small protein mediator pro-
duced by numerous cell types, including alveolar macro-
phages [30], neutrophils [31], pulmonary epithelial cells
[32], and pulmonary endothelial cells [32, 33]. During
severe infection, MIF accumulates both in the parenchymal
tissue and in the alveolar spaces. The intra-alveolar MIF
interacts with CD74 expressed on the surface of alveolar
macrophage cells, inducing p44/p42 MAPK activation and
chemokine release [35]. Furthermore, the MIF can be
released into the systemic circulation where it induces
cardiocirculatory depression [34, 36]. Notably, the increase
in MIF was concurrent with a significant decrease in free
T4 (Fig. 4). T4 has been shown to be a potent natural
inhibitor of MIF, and that plasma MIF and fT4 concen-
trations are inversely correlated in patients with severe
sepsis [26]. The study also showed that in thyroid-deficient
animals, the outcome from severe infection is worse than
euthyroid animals, and that inhibition of MIF with the
hormonally inactive D-isomer of T4 protects against
mortality. Furthermore, Ma et al. [54] have shown that
acute lung injury is associated with an upregulation of type
2 deiodinase (DIO2) which metabolizes T4 into tri-
iodothyronine (T3), a molecule involved in surfactant
homeostasis and lung compliance [55, 56]. Thus, there may
be many reasons for the low fT4 during acute lung injury.
However, reduced availability of T4 may have profound
downstream effects on lung function. This may be of par-
ticular importance to the older population, in whom an
existing mild or subclinical hypothyroidism is more com-
mon [57], may also worsen many risk factors [58], and be
directly related to the severity of acute illness [31].
Summary
Changes in pulmonary physiology, pathology, and function
are common in older populations, and lead to altered
responses and increased morbidity and mortality associated
with lung infections. However, in many respects, the rea-
sons for the altered susceptibility remain unclear. There
may be interactions between inflammatory and metabolic
pathways, such as with MIF and T4, or T3 and surfactant
homeostasis, that are not immediately obvious. While the
benefit of direct supplementation of thyroid hormones in
patients with critical illnesses such as ARDS or sepsis
remains unclear [59], perhaps addressing the possible
causes of the deficiency may prove more effective, as they
have in animal models [11, 26, 54, 60, 61]. What is clear is
that a better understanding of age-related changes in the
innate and adaptive immune systems within the pulmonary
compartment, and their impact on lung host defense, is of
critical importance for developing effective therapeutic
strategies for the treatment of the elderly patient.
Acknowledgments The authors thank Ms. Erica Spessot for assis-
tance with editing of the manuscript. Financial support for this work
was from The National Institutes of Health: NIH R01-HL 081655
(EJM), The Swedish Research Council (HML) and Swedish Society
for Medical Research (HML).
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Janssens JP, Pache JC,NicodLP. Physiological changes in respiratory
function associated with ageing. Eur Respir J. 1999;13(1):197–205.
2. Janssens JP, Krause KH. Pneumonia in the very old. Lancet Infect
Dis. 2004;4(2):112–24. doi:10.1016/S1473-3099(04)00931-4.
Feinstein Institute for Medical Research Immunology (2015) 63:209–215 213
123
3. Janssens JP. Pneumonia in the elderly (geriatric) population. Curr
Opin Pulm Med. 2005;11(3):226–30.
4. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Ger-
lach H, et al. Sepsis in European intensive care units: results of
the SOAP study. Crit Care Med. 2006;34(2):344–53.
5. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND,
Caldwell E, Fan E, et al. Acute respiratory distress syndrome: the
Berlin definition. JAMA. 2012;307(23):2526–33. doi:10.1001/
jama.2012.5669.
6. Kuzovlev AN, Moroz VV, Goloubev AM, Polovnikov SG.
Diagnosis of acute respiratory distress syndrome in nosocomial
pneumonia. Semin Cardiothorac Vasc Anesth.
2010;14(4):231–41. doi:10.1177/1089253210388297.
7. Miller EJ, Cohen AB, Nagao S, Griffith D, Maunder RJ, Martin
TR, et al. Elevated levels of NAP-1/interleukin-8 are present in
the airspaces of patients with the adult respiratory distress syn-
drome and are associated with increased mortality. Am Rev
Respir Dis. 1992;146(2):427–32.
8. Miller EJ, Cohen AB, Matthay MA. Increased interleukin-8
concentrations in the pulmonary edema fluid of patients with
acute respiratory distress syndrome from sepsis. Crit Care Med.
1996;24(9):1448–54.
9. Maus U, von Grote K, Kuziel WA, Mack M, Miller EJ, Cihak J,
et al. The role of CC chemokine receptor 2 in alveolar monocyte
and neutrophil immigration in intact mice. Am J Respir Crit Care
Med. 2002;166(3):268–73.
10. Donnelly SC, Haslett C, Reid PT, Grant IS, Wallace WA, Metz CN,
et al. Regulatory role for macrophage migration inhibitory factor in
acute respiratory distress syndrome. Nat Med. 1997;3(3):320–3.
11. Sakuragi T, Lin X, Metz CN, Ojamaa K, Kohn N, Al-Abed Y, et al.
Lung-derived macrophage migration inhibitory factor in sepsis
induces cardio-circulatory depression. Surg Infect (Larchmt).
2007;8(1):29–40.
12. Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ,
Voelter W, et al. MIF is a pituitary-derived cytokine that
potentiates lethal endotoxaemia. Nature. 1993;365(6448):756–9.
doi:10.1038/365756a0.
13. Hou G, Valujskikh A, Bayer J, Stavitsky AB, Metz C, Heeger PS.
In vivo blockade of macrophage migration inhibitory factor
prevents skin graft destruction after indirect allorecognition.
Transplantation. 2001;72(12):1890–7.
14. Lai KN, Leung JC, Metz CN, Lai FM, Bucala R, Lan HY. Role
for macrophage migration inhibitory factor in acute respiratory
distress syndrome. J Pathol. 2003;199(4):496–508. doi:10.1002/
path.1291.
15. Dios A, Mitchell RA, Aljabari B, Lubetsky J, O’Connor K, Liao
H, et al. Inhibition of MIF bioactivity by rational design of
pharmacological inhibitors of MIF tautomerase activity. J Med
Chem. 2002;45(12):2410–6.
16. Al-Abed Y, Dabideen D, Aljabari B, Valster A, Messmer D,
Ochani M, et al. ISO-1 binding to the tautomerase active site of
MIF inhibits its pro-inflammatory activity and increases survival
in severe sepsis. J Biol Chem. 2005;280(44):36541–4. doi:10.
1074/jbc.C500243200.
17. Crichlow GV, Cheng KF, Dabideen D, Ochani M, Aljabari B,
Pavlov VA, et al. Alternative chemical modifications reverse the
binding orientation of a pharmacophore scaffold in the active site
of macrophage migration inhibitory factor. J Biol Chem.
2007;282(32):23089–95.
18. Dabideen DR, Cheng KF, Aljabari B, Miller EJ, Pavlov VA, Al-
Abed Y. Phenolic hydrazones are potent inhibitors of macro-
phage migration inhibitory factor proinflammatory activity and
survival improving agents in sepsis. J Med Chem. 2007;
50(8):1993–7.
19. Atsumi T, Cho YR, Leng L, McDonald C, Yu T, Danton C, et al.
The proinflammatory cytokine macrophage migration inhibitory
factor regulates glucose metabolism during systemic inflamma-
tion. J Immunol. 2007;179(8):5399–406.
20. Matsuda N, Nishihira J, Takahashi Y, Kemmotsu O, Hattori Y.
Role of macrophage migration inhibitory factor in acute lung
injury in mice with acute pancreatitis complicated by endotox-
emia. Am J Respir Cell Mol Biol. 2006;35(2):198–205. doi:10.
1165/rcmb.2005-0272OC.
21. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M,
Donnelly T, et al. MIF as a glucocorticoid-induced modulator of
cytokine production. Nature. 1995;377(6544):68–71. doi:10.
1038/377068a0.
22. Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken
PN, Hyzy R, et al. Efficacy and safety of corticosteroids for
persistent acute respiratory distress syndrome. N Engl J Med.
2006;354(16):1671–84. doi:10.1056/NEJMoa051693.
23. Annane D. Glucocorticoids for ARDS: just do it! Chest.
2007;131(4):945–6. doi:10.1378/chest.06-3005.
24. Ruan SY, Lin HH, Huang CT, Kuo PH, Wu HD, Yu CJ.
Exploring the heterogeneity of effects of corticosteroids on acute
respiratory distress syndrome: a systematic review and meta-
analysis. Crit Care. 2014;18(2):R63. doi:10.1186/cc13819.
25. Fliers E, Bianco AC, Langouche L, Boelen A. Thyroid function
in critically ill patients. Lancet Diabetes Endocrinol. 2015.
doi:10.1016/S2213-8587(15)00225-9.
26. Al-Abed Y, Metz CN, Cheng KF, Aljabari B, VanPatten S, Blau
S, et al. Thyroxine is a potential endogenous antagonist of
macrophage migration inhibitory factor (MIF) activity. Proc Natl
Acad Sci USA. 2011;108(20):8224–7.
27. Zhang Y, Lin X, Koga K, Takahashi K, Linge HM, Mello A,
et al. Strain differences in alveolar neutrophil infiltration and
macrophage phenotypes in an acute lung inflammation model.
Mol Med. 2011;17(7–8):780–9.
28. Frevert CW, Huang S, Danaee H, Paulauskis JD, Kobzik L.
Functional characterization of the rat chemokine KC and its
importance in neutrophil recruitment in a rat model of pulmonary
inflammation. J Immunol. 1995;154(1):335–44.
29. Gao L, Flores C, Fan-Ma S, Miller EJ, Moitra J, Moreno L, et al.
Macrophage migration inhibitory factor in acute lung injury:
expression, biomarker, and associations. Transl Res.
2007;150(1):18–29.
30. Lin X, Sakuragi T, Metz CN, Ojamaa K, Skopicki HA, Wang P,
Al-Abed Y, Miller EJ. Macrophage migration inhibitory factor
within the alveolar spaces induces changes in the heart during late
experimental sepsis. Shock. 2005;24(6):556–63.
31. Kaptein EM, Weiner JM, Robinson WJ, Wheeler WS, Nicoloff
JT. Relationship of altered thyroid hormone indices to survival in
nonthyroidal illnesses. Clin Endocrinol (Oxf). 1982;
16(6):565–74.
32. Kang CI, Song JH, Ko KS, Chung DR, Peck KR. Clinical features
and outcome of Staphylococcus aureus infection in elderly versus
younger adult patients. Int J Infect Dis. 2011;15(1):e58–62.
doi:10.1016/j.ijid.2010.09.012.
33. Schreiber MP, Chan CM, Shorr AF. Bacteremia in Staphylo-
coccus aureus pneumonia: outcomes and epidemiology. J Crit
Care. 2011;26(4):395–401. doi:10.1016/j.jcrc.2010.09.002.
34. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Raga-
Luria X, Gomez-Bertomeu F. Epidemiology of community-ac-
quired pneumonia in older adults: a population-based study.
Respir Med. 2009;103(2):309–16.
35. Meyer KC, Ershler W, Rosenthal NS, Lu XG, Peterson K.
Immune dysregulation in the aging human lung. Am J Respir Crit
Care Med. 1996;153(3):1072–9.
36. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP,
Neff M, et al. Incidence and outcomes of acute lung injury.
N Engl J Med. 2005;353(16):1685–93. doi:10.1056/
NEJMoa050333.
214 Feinstein Institute for Medical Research Immunology (2015) 63:209–215
123
37. Kuzovlev AN, Moroz VV, Goloubev AM, Polovnikov SG.
Diagnosis of acute respiratory distress syndrome in nosocomial
pneumonia. Semin Cardiothorac Vasc Anesth.
2010;14(4):231–41. doi:10.1177/1089253210388297.
38. Bull TM, Clark B, McFann K, Moss M. Pulmonary vascular
dysfunction is associated with poor outcomes in patients with
acute lung injury. Am J Respir Crit Care Med. 2010;
182(9):1123–8.
39. Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT,
Hayden D, deBoisblanc B, et al. Comparison of two fluid-man-
agement strategies in acute lung injury. N Engl J Med. 2006;
354(24):2564–75.
40. Erickson SE, Shlipak MG, Martin GS, Wheeler AP, Ancukiewicz
M, Matthay MA, et al. Racial and ethnic disparities in mortality
from acute lung injury. Crit Care Med. 2009;37(1):1–6.
41. Wheeler AP, Bernard GR, Thompson BT, Schoenfeld D,
Wiedemann HP, deBoisblanc B, et al. Pulmonary-artery versus
central venous catheter to guide treatment of acute lung injury.
N Engl J Med. 2006;354(21):2213–24.
42. Cribbs SK, Martin GS. Fluid balance and colloid osmotic pres-
sure in acute respiratory failure: optimizing therapy. Expert Rev
Respir Med. 2009;3(6):651–62.
43. Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M,
Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on
immunosenescence. Ann NY Acad Sci. 2000;908:244–54.
44. Bruunsgaard H, Pedersen M, Pedersen BK. Aging and proin-
flammatory cytokines. Curr Opin Hematol. 2001;8(3):131–6.
45. Krabbe KS, Pedersen M, Bruunsgaard H. Inflammatory mediators
in the elderly. Exp Gerontol. 2004;39(5):687–99.
46. Starr ME, Saito H. Sepsis in old age: review of human and animal
studies. Aging Dis. 2014;5(2):126–36. doi:10.14336/AD.2014.
0500126.
47. Saito H, Sherwood ER, Varma TK, Evers BM. Effects of aging
on mortality, hypothermia, and cytokine induction in mice with
endotoxemia or sepsis. Mech Ageing Dev. 2003;124(10–12):
1047–58.
48. Linge HM, Lee JY, Ochani K, Koga K, Kohn N, Ojamaa K, et al.
Age influences inflammatory responses, hemodynamics, and
cardiac proteasome activation during acute lung injury. Exp Lung
Res. 2015;41(4):216–27.
49. Starr ME, Evers BM, Saito H. Age-associated increase in cyto-
kine production during systemic inflammation: adipose tissue as a
major source of IL-6. J Gerontol A Biol Sci Med Sci.
2009;64(7):723–30. doi:10.1093/gerona/glp046.
50. Naffaa M, Makhoul BF, Tobia A, Kaplan M, Aronson D, Saliba
W, et al. Interleukin-6 at discharge predicts all-cause mortality in
patients with sepsis. Am J Emerg Med. 2013;31(9):1361–4.
doi:10.1016/j.ajem.2013.06.011.
51. Nijhuis J, Rensen SS, Slaats Y, van Dielen FM, Buurman WA,
Greve JW. Neutrophil activation in morbid obesity, chronic
activation of acute inflammation. Obesity (Silver Spring).
2009;17(11):2014–8. doi:10.1038/oby.2009.113.
52. Ayala A, Chung CS, Lomas JL, Song GY, Doughty LA, Gregory
SH, et al. Shock-induced neutrophil mediated priming for acute
lung injury in mice: divergent effects of TLR-4 and TLR-4/FasL
deficiency. Am J Pathol. 2002;161(6):2283–94. doi:10.1016/
S0002-9440(10)64504-X.
53. Walz A, Peveri P, Aschauer H, Baggiolini M. Purification and
amino acid sequencing of NAF, a novel neutrophil-activating
factor produced by monocytes. Biochem Biophys Res Commun.
1987;149(2):755–61. doi:10.1016/0006-291X(87)90432-3.
54. Ma SF, Xie L, Pino-Yanes M, Sammani S, Wade MS, Letsiou E,
et al. Type 2 deiodinase and host responses of sepsis and acute
lung injury. Am J Respir Cell Mol Biol. 2011;45(6):1203–11.
doi:10.1165/rcmb.2011-0179OC.
55. Ksenzenko SM, Davidson SB, Saba AA, Franko AP, Raafat AM,
Diebel LN, et al. Effect of triiodothyronine augmentation on rat
lung surfactant phospholipids during sepsis. J Appl Physiol.
1997;82(6):2020–7.
56. Raafat AM, Franko AP, Zafar R, Dulchavsky SA, Diebel LN,
Ksenzenko S. Effect of thyroid hormone (T3)-responsive changes
in surfactant apoproteins on surfactant function during sepsis.
J Trauma. 1997;42(5):803–8; discussion 8–9.
57. Hennessey JV, Espaillat R. Diagnosis and Management of Sub-
clinical Hypothyroidism in elderly adults: a review of the liter-
ature. J Am Geriatr Soc. 2015. doi:10.1111/jgs.13532.
58. Iervasi G, Molinaro S, Landi P, Taddei MC, Galli E, Mariani F,
et al. Association between increased mortality and mild thyroid
dysfunction in cardiac patients. Arch Intern Med.
2007;167(14):1526–32. doi:10.1001/archinte.167.14.1526.
59. Stathatos N, Levetan C, Burman KD, Wartofsky L. The contro-
versy of the treatment of critically ill patients with thyroid hor-
mone. Best Pract Res Clin Endocrinol Metab. 2001;15(4):
465–78. doi:10.1053/beem.2001.0164.
60. Takahashi K, Koga K, Linge HM, Zhang Y, Lin X, Metz CN,
et al. Macrophage CD74 contributes to MIF-induced pulmonary
inflammation. Respir Res. 2009;10(33):1–14.
61. Lin X, Yang H, Sakuragi T, Hu M, Mantell LL, Hayashi S, et al.
Alpha-chemokine receptor blockade reduces high mobility group
box 1 protein-induced lung inflammation and injury and improves
survival in sepsis. Am J Physiol Lung Cell Mol Physiol.
2005;289(4):L583–90.
Feinstein Institute for Medical Research Immunology (2015) 63:209–215 215
123
